Innovative Birth Control Method: A Low-Dose, Once-Weekly Contraceptive Patch, Phase 3 Trials
Nov 21st 2008Drug InformationSexual Health
Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women’s health products, announced today that after a successful end-of-Phase 2 meeting with the Food and Drug Administration (FDA), the company is moving forward with its pivotal Phase 3 program to support a NDA filing and marketing approval of AG200-15 with SKINFUSION? technology. AG200-15 is an innovative, low-dose contraceptive patch that offers women a convenient, once-weekly form of birth control.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
